Matharu Nick M, Butler Lynn M, Rainger G Ed, Gosling Peter, Vohra Rajiv K, Nash Gerard B
Centre for Cardiovascular Science, University of Birmingham, Birmingham, UK.
Crit Care Med. 2008 May;36(5):1536-42. doi: 10.1097/CCM.0b013e318169f19a.
To determine whether plasma volume expander hydroxyethyl starch (HES) may protect against reperfusion injury through an ability to reduce neutrophil recruitment.
An in vitro study using paired comparisons of adhesion of flowing neutrophils.
A collaboration between clinical and basic science departments in a university hospital.
Neutrophils and cultured human umbilical vein endothelial cells (HUVEC).
Treatment with HES (average molecular weight of 200 kd and substitution of 0.62) at clinically relevant concentrations or with gelatin solution (average molecular weight of 30 kDa) of comparable viscosity.
Glass capillaries were coated internally with either purified adhesion molecules or HUVEC, which were treated with tumor necrosis factor-alpha in the presence or absence of HES. Neutrophils were perfused over these surfaces (with or without HES) and their recruitment quantified by video microscopy. Expression of adhesion molecules and of the chemokine interleukin-8 by HUVEC were analyzed by enzyme-linked immunosorbent assay and quantitation of messenger RNA. HES over a wide range of concentrations had no effect on selectin- or integrin-mediated adhesion of neutrophils. However, when HUVEC were cultured with 1.5% wt/vol HES, neutrophil capture induced by low-dose (1 unit/mL) tumor necrosis factor-alpha and transendothelial migration induced by high-dose (100 units/mL) tumor necrosis factor-alpha were significantly inhibited (p < .05, in each case). The effects were linked with reductions in expression of E-selectin and interleukin-8 by HUVEC at these respective tumor necrosis factor-alpha concentrations (p < .05, in each case). Gelatin (2% wt/vol) had no significant effect in assays with HUVEC.
Application of HES to HUVEC exerts an inhibitory effect on different stages of neutrophil recruitment, depending on the level of the inflammatory stimulus. These effects are associated with reduced adhesion molecule expression and chemokine production. In vivo, comparable effects might protect against complications associated with reperfusion injury.
确定血浆容量扩充剂羟乙基淀粉(HES)是否可通过减少中性粒细胞募集的能力来预防再灌注损伤。
一项使用流动中性粒细胞黏附配对比较的体外研究。
一所大学医院临床与基础科学部门之间的合作。
中性粒细胞和培养的人脐静脉内皮细胞(HUVEC)。
用临床相关浓度的HES(平均分子量200kd,取代度0.62)或具有可比粘度的明胶溶液(平均分子量30kDa)进行处理。
玻璃毛细管内部包被纯化的黏附分子或HUVEC,后者在有或无HES的情况下用肿瘤坏死因子-α处理。中性粒细胞灌注于这些表面(有或无HES),通过视频显微镜对其募集进行定量。通过酶联免疫吸附测定和信使核糖核酸定量分析HUVEC黏附分子和趋化因子白细胞介素-8的表达。大范围浓度的HES对选择素或整合素介导的中性粒细胞黏附无影响。然而,当HUVEC与1.5%重量/体积的HES一起培养时,低剂量(1单位/mL)肿瘤坏死因子-α诱导的中性粒细胞捕获和高剂量(100单位/mL)肿瘤坏死因子-α诱导的跨内皮迁移均受到显著抑制(每种情况均为p<0.05)。这些效应与在这些各自的肿瘤坏死因子-α浓度下HUVEC的E-选择素和白细胞介素-8表达降低有关(每种情况均为p<0.05)。2%重量/体积的明胶在HUVEC检测中无显著影响。
将HES应用于HUVEC对中性粒细胞募集的不同阶段产生抑制作用,这取决于炎症刺激的程度。这些效应与黏附分子表达降低和趋化因子产生减少有关。在体内,类似效应可能预防与再灌注损伤相关的并发症。